Last updated on

Journal of Clinical Oncology
Research Hotspot & Journal Scope - II


Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.5005
TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations

Joaquin Mateo · Nuria Porta · U. McGovern · Tony Elliott · Robert Jones · Isabel Syndikus · Christy Ralph · Suneil Jain · Mohini Varughese · O. Parikh · Simon J. Crabb · Susana Miranda · George Seed · Claudia Bertan · Aude Espinasse · Peter Chatfield · Diletta Bianchini · Emma Hall · Suzanne Carreira · Johann S. de Bono ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.1005
Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.

Robert Hugh Jones · Margherita Carucci · Angela C. Casbard · Rachel Butler · Fouad S Alchami · Catherine Jane Bale · Pavel Bezecny · Johnathan Joffe · Sarah Moon · Chris Twelves · Ramachandran Venkitaraman · Simon Waters · Sacha J Howell ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.3501
Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).

Timothy Iveson · Alberto Sobrero · Takayuki Yoshino · Ioannis Sougklakos · Fang-Shu Ou · Jeffery P. Meyers · Qian Shi · Mark P Saunders · Roberto Labianca · Takeharu Yamanaka · Ioannis Boukovinas · Niels Henrik Hollander · Valter Torri · Kentaro Yamazaki · Vassilis Georgoulias · Sara Lonardi · Andrea Harkin · Gerardo Rosati · James Paul ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.4_SUPPL.129
Phase I/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma (NivoRam study).

Hiroki Hara · Hirokazu Shoji · Daisuke Takahari · Taito Esaki · Nozomu Machida · Kengo Nagashima · Kazunori Aoki · Kazufumi Honda · Takahiro Miyamoto · Narikazu Boku · Ken Kato ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.19.01507
Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer

Carryn M Anderson · Christopher M Lee · Deborah P Saunders · Amarinthia Curtis · Neal Dunlap · Chaitali Nangia · Arielle S Lee · Sharon M Gordon · Philip Kovoor · Roberto Arevalo-Araujo · Voichita Bar-Ad · Abhinand Peddada · Kyle Colvett · Douglas Miller · Anshu K Jain · James Wheeler · Dukagjin Blakaj · Marcelo Bonomi · Sanjiv S Agarwala · Madhur Garg · Francis Worden · Jon Holmlund · Jeffrey M Brill · Matt Downs · Stephen T Sonis · Sanford Katz · John M Buatti ·

Medicine
PDF

Nine half-sandwich IrIII complexes [(η5-Cpx)Ir(NˆN)Cl]PF6, where Cpx is Cp* or its phenyl Cpxph or biphenyl Cpxbiph derivative and NˆN is a triphenylamine (TPA)-substituted bipyridyl ligand, were synthesized and characterized.

Half-sandwich Iridium(III) complexes with triphenylamine-substituted dipyridine frameworks and bioactivity applications [10.1016/J.DYEPIG.2018.08.006]


They proposed the name Acinetobacter lwoffii for GS8, which included the supposed type strain (CIP 64.

Revising the taxonomy of the Acinetobacter lwoffii group: The description of Acinetobacter pseudolwoffii sp. nov. and emended description of Acinetobacter lwoffii. [10.1016/j.syapm.2018.10.004]


This study describes a three-dimensional finite element model developed to assist in determining the mode II interlaminar fracture toughness (G IIc) of fibre-reinforced woven composites, validated by an experimental and numerical comparison of G IIc determination for unidirectional FRPMC.

Experimental and numerical determination of mode II fracture toughness of woven composites verified through unidirectional composite test data [10.1177/0967391119853736]


In this paper, we propose maximum likelihood estimators (MLEs) and Bayes estimators of parameters of the step-stress partially accelerated life testing of Rayleigh distribution in presence of progressive type-II censoring with binomial removal scheme under Square error loss function, General entropy loss function and Linear exponential loss function.

Bayesian Inference for Rayleigh Distribution Under Step-Stress Partially Accelerated Test with Progressive Type-II Censoring with Binomial Removal [10.1007/S40745-019-00192-W]


Sanfilippo syndrome type B (Sanfilippo B; Mucopolysaccharidosis type IIIB) occurs due to genetic deficiency of lysosomal alpha-N-acetylglucosaminidase (NAGLU) and subsequent lysosomal accumulation of heparan sulfate (HS), which coincides with devastating neurodegenerative disease.

BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis [10.1371/journal.pone.0207836]


Highly Related Keywords from II

Research Hotspot

Journal of Clinical Oncology

Research Hotspot
Journal of Clinical Oncology Related Journals

Popular Journals